Loading
A phase 3 trial of Cisplatin and Sodium thiosulfate in Hepatocellular carcinoma, run by University of Birmingham, completed.
Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer is a phase 3 interventional study registered as NCT00652132 by University of Birmingham, with 116 participants recorded, started 2007-12-15 and reaching its primary completion in 2017-09-04. Interventions recorded: cisplatin, sodium thiosulfate. Conditions recorded: Liver Cancer, Ototoxicity.
Linked to the drug Sodium thiosulfate because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sodium thiosulfate (otoprotectant), Hearing and tinnitus after platinum chemotherapy, Hepatocellular carcinoma and the tag pipeline.
Shares Sodium thiosulfate (otoprotectant), Cisplatin and the tag pipeline.
Shares Cisplatin, Hepatocellular carcinoma and the tag pipeline.
Shares Cisplatin, Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/